Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 18, 2020 at 8:42 PM.

  1. #1 cafead, Feb 18, 2020 at 8:42 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via Wedding Five Prime Therapeutics’ experimental CSF-1 receptor inhibitor cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved a bust in pancreatic cancer.

    article source
     
    Quote

Reply to Thread